Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other 1Gynecologic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Progesterone Resistance 1Polycystic Ovary Syndrome 1Obesity 1Endometrial Neoplasms 1Endometrial Hyperplasia 1

Interventions

pembrolizumab 603Cyclophosphamide 545Magnetic Resonance Spectroscopy 527Radiotherapy 513Specimen Handling 505Nivolumab 411Cisplatin 381Carboplatin 369Biopsy 305Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 263Dexamethasone 263Bevacizumab 252venetoclax 251Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 191Ipilimumab 188Fluorouracil 188durvalumab 185Doxorubicin 178Etoposide 177atezolizumab 172

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- × 1 year × Clear all
NCT05326087 2026-02-02

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

ShangHai Ji Ai Genetics & IVF Institute

Phase 3 Not yet recruiting
204 enrolled

Polycystic Ovary Syndrome

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

OHSU Knight Cancer Institute

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT06379113 2025-08-11

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Fudan University

Phase 2/3 Recruiting
29 enrolled
GynecologicOther

Progesterone Resistance, Endometrial Hyperplasia, Obesity, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡